Komfoderm M2, cream 30 g

A product with anti-inflammatory and keratolytic effect for external use.

Indications

Inflammatory skin diseases, sensitive to therapy with topical glucocorticosteroids and accompanied by impaired keratinization:

— atopic dermatitis, neurodermatitis;

– true eczema;

– microbial eczema;

– simple contact dermatitis;

– allergic (contact) dermatitis;

– dyshidrotic eczema.

Pharmacological effect

A drug with anti-inflammatory and keratolytic effects for external use.

Special instructions

In the presence of bacterial complications and/or dermatomycosis, in addition to therapy with Comfoderm® M2, it is necessary to carry out specific antibacterial and/or antifungal treatment.

The drug is not intended for use in ophthalmology. Avoid contact of the drug with the eyes and mucous membranes.

As with the use of systemic glucocorticoids, glaucoma may develop with external use of GCS (for example, after use in high doses, due to very long-term use, use of occlusive dressings or application to the skin around the eyes). On the skin of the face more often than on other surfaces of the body, after long-term treatment with GCS for external use, atrophic changes may develop.

Impact on the ability to drive vehicles and operate machinery

Not identified.

Active ingredient

Methylprednisolone aceponate, Urea

Composition

100 g of cream contains:

Active ingredients: methylprednisolone aceponate 100 mg; urea 2 g;

Excipients: liquid paraffin (vaseline oil) – 15 g, propylene glycol – 5 g, polysorbate 80 – 1 g, carbomer interpolymer (type A) – 1 g, trometamol – 400 mg, methyl parahydroxybenzoate – 100 mg, purified water – up to 100 g.

Contraindications

– hypersensitivity to the components of the drug;

– tuberculosis or syphilitic processes in the area of ​​​​application of the drug;

– viral diseases (for example, chicken pox, herpes zoster);

— rosacea, perioral dermatitis in the area of ​​application of the drug;

– areas of skin with manifestations of a reaction to vaccination;

– children under 18 years of age.

Side Effects

Very rarely (in less than 0.01% of cases) local reactions may be observed, such as itching, burning, erythema, and the formation of a vesicular rash.

If the drug is used for more than 4 weeks and/or on an area of ​​10% or more of the body surface, the following reactions may occur: skin atrophy, telangiectasia, striae, acneiform skin changes, systemic effects due to corticosteroid absorption.

In rare cases (0.01%-0.1%), folliculitis, hypertrichosis, perioral dermatitis, skin depigmentation, and allergic reactions to one of the components of the drug may occur.

Interaction

No interaction of the drug with other drugs has been identified, however, it should be borne in mind that the simultaneous use of Comfoderm® M2 with other ointments or creams may lead to increased resorption of their constituent drugs.

Overdose

Symptoms: with excessively long and/or intensive local use of GCS, skin atrophy (thinning of the skin, telangiectasia, striae) may develop.

Treatment: if signs of skin atrophy appear, the drug must be discontinued.

Storage conditions

The drug should be stored out of the reach of children at a temperature not exceeding 25°C.

Shelf life

2 years.

Manufacturer

Akrikhin JSC, Russia